Logo image of HLVX

HILLEVAX INC (HLVX) Stock Fundamental Analysis

NASDAQ:HLVX - US43157M1027 - Common Stock

2.09 USD
+0.01 (+0.48%)
Last: 8/29/2025, 8:00:01 PM
2.08 USD
-0.01 (-0.48%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to HLVX. HLVX was compared to 545 industry peers in the Biotechnology industry. HLVX has a great financial health rating, but its profitability evaluates not so good. HLVX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HLVX has reported negative net income.
HLVX had a negative operating cash flow in the past year.
HLVX had negative earnings in each of the past 5 years.
In the past 5 years HLVX always reported negative operating cash flow.
HLVX Yearly Net Income VS EBIT VS OCF VS FCFHLVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

HLVX has a Return On Assets (-40.65%) which is in line with its industry peers.
HLVX's Return On Equity of -48.10% is fine compared to the rest of the industry. HLVX outperforms 66.18% of its industry peers.
Industry RankSector Rank
ROA -40.65%
ROE -48.1%
ROIC N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLVX Yearly ROA, ROE, ROICHLVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

HLVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLVX Yearly Profit, Operating, Gross MarginsHLVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, HLVX has more shares outstanding
HLVX has more shares outstanding than it did 5 years ago.
HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HLVX Yearly Shares OutstandingHLVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HLVX Yearly Total Debt VS Total AssetsHLVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

HLVX has an Altman-Z score of -1.99. This is a bad value and indicates that HLVX is not financially healthy and even has some risk of bankruptcy.
HLVX has a Altman-Z score (-1.99) which is in line with its industry peers.
HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.99
ROIC/WACCN/A
WACCN/A
HLVX Yearly LT Debt VS Equity VS FCFHLVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

HLVX has a Current Ratio of 26.39. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 26.39, HLVX belongs to the best of the industry, outperforming 97.08% of the companies in the same industry.
A Quick Ratio of 26.39 indicates that HLVX has no problem at all paying its short term obligations.
HLVX's Quick ratio of 26.39 is amongst the best of the industry. HLVX outperforms 97.08% of its industry peers.
Industry RankSector Rank
Current Ratio 26.39
Quick Ratio 26.39
HLVX Yearly Current Assets VS Current LiabilitesHLVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.82% over the past year.
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HLVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.16% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.34%
EPS Next 2Y35.78%
EPS Next 3Y22.84%
EPS Next 5Y10.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HLVX Yearly Revenue VS EstimatesHLVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 20M 40M 60M
HLVX Yearly EPS VS EstimatesHLVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HLVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HLVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLVX Price Earnings VS Forward Price EarningsHLVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLVX Per share dataHLVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

HLVX's earnings are expected to grow with 22.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.78%
EPS Next 3Y22.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HLVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HILLEVAX INC

NASDAQ:HLVX (8/29/2025, 8:00:01 PM)

After market: 2.08 -0.01 (-0.48%)

2.09

+0.01 (+0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)N/A N/A
Inst Owners53.82%
Inst Owner Change-1.64%
Ins Owners2.32%
Ins Owner Change1.26%
Market Cap104.79M
Analysts45.71
Price Target2.04 (-2.39%)
Short Float %1.47%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.37%
Min EPS beat(2)22.97%
Max EPS beat(2)67.77%
EPS beat(4)2
Avg EPS beat(4)-8.83%
Min EPS beat(4)-104.08%
Max EPS beat(4)67.77%
EPS beat(8)4
Avg EPS beat(8)-4.94%
EPS beat(12)8
Avg EPS beat(12)10.04%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)11.11%
EPS NQ rev (3m)N/A
EPS NY rev (1m)15.52%
EPS NY rev (3m)15.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS2.95
TBVpS2.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.65%
ROE -48.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.39
Quick Ratio 26.39
Altman-Z -1.99
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.75%
EPS Next Y83.34%
EPS Next 2Y35.78%
EPS Next 3Y22.84%
EPS Next 5Y10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.42%
OCF growth 3YN/A
OCF growth 5YN/A